| Literature DB >> 29582395 |
Andreas Synetos1, Konstantinos Toutouzas2, Maria Drakopoulou2, Iosif Koutagiar2, George Benetos2, Rafail Kotronias2, Nikolaos Anousakis-Vlachochristou2, George Latsios2, Antonis Karanasos2, George Agrogiannis3, Marinos Metaxas4, Konstantinos Stathogiannis2, Aggelos Papanikolaou2, Alexandros Georgakopoulos4, Nikoleta Pianou4, Eleftherios Tsiamis2, Efstratios Patsouris3, Apostolos Papalois5, Dennis Cokkinos4, Constantinos Anagnostopoulos4, Dimitrios Tousoulis2.
Abstract
The aim of this study was to evaluate in an experimental model of aortic valve (AV) stenosis the effectiveness of zoledronate on the inhibition of calcification. Sixteen New Zealand rabbits were placed on vitamin D-enriched diet for 3 weeks. All animals underwent PET/CT at baseline and before euthanasia to assess calcification. Thereafter, the AVs of eight animals were treated with local delivery of 500 μg/l zoledronate. A placebo mixture was administered in the remaining eight animals. Standardized uptake values were corrected for blood pool activity, providing mean tissue to background ratios (TBRmean). In the zoledronate group, there was no progression of AV calcification (TBRmean 1.20 ± 0.12 vs 1.17 ± 0.78,p = 0.29), while AV calcification progressed in the placebo group (1.22 ± 0.15 vs 1.53 ± 0.23,p = 0.006). Ascending aorta (AA) calcification progressed in both zoledronate and placebo groups. Histology confirmed the results of the PET/CT. Inhibition of AV calcification by local delivery of zoledronate is feasible and effective.Entities:
Keywords: Aortic valve; Bisphosphonates; Calcification
Mesh：
Substances：
Year: 2018 PMID： 29582395 DOI： 10.1007/s12265-018-9802-4
Source DB: PubMed Journal: J Cardiovasc Transl Res ISSN： 1937-5387 Impact factor: 4.132